Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), H. Joachim Deeg(University of Washington), Mehdi Hamadani(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hugo F. Fernández(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Asad Bashey, Erica D. Warlick(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Adam Mendizabal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jennifer Le‐Rademacher(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Eric Leifer(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Richard T. Maziarz(Oregon Health & Science University), Marcelo C. Pasquini(Medical College of Wisconsin), Mary M. Horowitz(Medical College of Wisconsin), David Porter(Texas Oncology), Nancy L. Geller(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Juan Wu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Steven M. Devine(National Marrow Donor Program)
Cited by 664
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k